A Prospective RegistrY of Cardiac Echographic Loops

NCT ID: NCT03371524

Last Updated: 2021-10-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-07-19

Study Completion Date

2019-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

CARDIAWAVE, a French start-up founded in 2014, aims to develop a new non-invasive therapy to treat patients suffering from Aortic Valve Stenosis (AS) who are not candidates to validated treatment of AS, i.e. TAVI (Transcatheter Aortic Valve Implantation) or SAVR (Surgical Aortic Valve Replacement). This therapy consists in focusing ultrasound on aortic valve transthoracically and use high energy to soften calcification from the target valve. In order to do so, we develop a device able to deliver high energy ultrasounds to a targeted valve thanks to the synchronization of patient hearts live imaging and therapy in real time.

Live imaging will use an algorithm to realize 'valve tracking': an automatic detection of aortic valve position and shape as fast as image acquisition time. In order to develop and validate this 'valve tracking' algorithm, CARDIAWAVE requires cardiac echographic loops of patients with aortic valve calcification, with 30 seconds or 60 seconds recording.

The objective of the present study is to develop and validate the 'valve tracking' processing algorithm of CARDIAWAVE.

ARYEL is a prospective, multicenter, non-interventional study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Calcified Aortic Valve

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Native valves_30 seconds loops

Patient with calcified aortic stenosis on native valve: record of a 30 second loop during routine cardiac echography.

Cardiac Echography

Intervention Type OTHER

While routine cardiac echography is performed on patients with calcified aortic valve, a 30 second loop is recorded.

Native valves_30 and 60 seconds loops

Patient with calcified aortic stenosis on native valve: record of a 30 second loop and a 60 second loop during routine cardiac echography.

Cardiac Echography

Intervention Type OTHER

While routine cardiac echography is performed on patients with calcified aortic valve, a 30 second loop is recorded.

Bioprosthesis_30 seconds loops

Patient with calcified aortic stenosis on bioprosthesis: record of a 30 second loop during routine cardiac echography.

Cardiac Echography

Intervention Type OTHER

While routine cardiac echography is performed on patients with calcified aortic valve, a 30 second loop is recorded.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cardiac Echography

While routine cardiac echography is performed on patients with calcified aortic valve, a 30 second loop is recorded.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged ≥ 18 y.o
* Patients with a confirmed diagnosis of Aortic valve calcification on native valve or bioprosthesis
* Patients with planned cardiac transthoracic echography for 'Aortic valve calcification' follow-up
* Patients who have signed Informed Consent Form
* Patients affiliated to French social security or equivalent

Exclusion Criteria

* Patients allergic to echographic gel
* Patients with "hostile thorax": serious cutaneous irradiation injury or major thoracic deformity.
* Low echogenicity
* Patients with mild or high abundance pericardic effusion
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cardiawave SA

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU de Caen

Caen, , France

Site Status

Hôpital Européen Georges Pompidou

Paris, , France

Site Status

Hôpital Charles Nicolle

Rouen, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ARYEL

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Valvular Heart Disease Registry
NCT03488732 RECRUITING